TMEM132C: A Transmembrane Protein with Potential as a Drug Target or Biomarker

Target Name: TMEM132C

NCBI ID: G92293

TMEM132C

TMEM132C: A Transmembrane Protein with Potential as a Drug Target or Biomarker

TMEM132C (Transmembrane protein 132C, transcript variant 1) is a gene encoding a protein that is expressed in various tissues and organs, including brain, heart, liver, and muscle. The protein is localized to the endoplasmic reticulum (ER) and has been shown to play a role in the regulation of cellular processes, including cell signaling, DNA replication, and cell survival.

TMEM132C has also been identified as a potential drug target or biomarker, which could be useful in the development of new therapeutic approaches for various diseases. In this article, we will discuss the structure, function, and potential clinical applications of TMEM132C.

Structure and Function

TMEM132C is a transmembrane protein that is expressed in the ER and has been shown to localize to the end of the cytosol. The protein has a molecular weight of approximately 42 kDa and consists of 154 amino acids. TMEM132C has a unique feature, which is the presence of a N-terminal transmembrane domain and a C-terminal cytoplasmic domain.

The N-terminal transmembrane domain is responsible for the protein's ability to interact with various signaling molecules, including neurotransmitters and cytokines. This domain is known to play a role in the regulation of neurotransmitter release and uptake, which is crucial for the function of the brain.

The C-terminal cytoplasmic domain is responsible for the protein's ability to interact with various intracellular signaling pathways, including the PI3K/Akt signaling pathway. This domain has been shown to play a role in the regulation of cellular processes, including cell survival and proliferation.

TMEM132C has been shown to interact with various signaling molecules, including the neurotransmitter dopamine and the cytokine PDGF-BB. These interactions may play a role in the regulation of cellular processes, including neurotransmitter release, uptake, and signaling.

Potential Clinical Applications

TMEM132C has the potential to be a drug target or biomarker for various diseases. One of the main advantages of TMEM132C is its expression in various tissues and organs, which makes it a potential therapeutic target for a variety of diseases.

One of the most promising applications of TMEM132C is its potential as a drug target for neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells, which can lead to a range of symptoms, including cognitive decline, behavioral changes, and motor dysfunction.

TMEM132C has been shown to play a role in the regulation of neurotransmitter release and uptake, which is crucial for the function of the brain. Therefore, inhibiting TMEM132C activity may be a potential therapeutic approach for neurodegenerative diseases.

TMEM132C may also be a potential biomarker for various diseases, including neurodegenerative diseases. The loss of brain cells in these conditions can lead to a decline in the levels of certain proteins, including TMEM132C. Therefore, measuring the levels of TMEM132C may be a useful diagnostic tool for neurodegenerative diseases.

Conclusion

TMEM132C is a transmembrane protein that is expressed in various tissues and organs and has been shown to play a role in the regulation of cellular processes, including cell signaling, DNA replication, and cell survival. The protein has a unique feature, which is the presence of a N-terminal transmembrane domain and a C-terminal cytoplasmic domain. TMEM132C has the potential to be a drug target or biomarker for various diseases, including neurodegenerative diseases. Further research is needed to fully understand the function

Protein Name: Transmembrane Protein 132C

The "TMEM132C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM132C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets